Boston Scientific amends $2.75B revolver: extends maturity to 2027, switches to SOFR, resets EBITDA exclusion base

BOSTON SCIENTIFIC CORP

Second amendment to $2.75B revolving credit agreement extends maturity from May 2026 to May 2027 for consenting lenders.
LIBOR replaced with Term SOFR plus credit spread adjustments for Eurocurrency Rate for Dollars.
Reference date for excluding Cash Litigation Payments from EBITDA reset from March 31, 2021 to December 31, 2022; cap remains $1B.
Reference date for excluding restructuring charges from EBITDA also reset to December 31, 2022; cap remains $500M.
Amendment effective March 1, 2023; Wells Fargo remains administrative agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.